Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Lorediplon. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 1/20 | 0.37 |
| ▸ | GABRG2 known ✓ | P18507 | 1/20 | 0.37 |
| ▸ | GABRB3 known ✓ | P28472 | 1/20 | 0.37 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.37 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.37 |
| ▸ | CDKN1A | P38936 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 6/20 | 0.40 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lorediplon SCHEMBL29376531 | 1.00 | CDKN1A (0.54) | CDKN1AKDM4ETLR8ALDH1A1BRAF | |
| SCHEMBL2107990 | 0.90 | CDKN1A (0.55) | CDKN1AKDM4ETLR8ALDH1A1BRAF | |
| SCHEMBL3241433 | 0.90 | CDKN1A (0.54) | CDKN1AKDM4ETLR8ALDH1A1BRAF | |
| SCHEMBL2108079 | 0.88 | CDKN1A (0.53) | CDKN1AKDM4ETLR8ALDH1A1BRAF | |
| SCHEMBL3243650 | 0.88 | CDKN1A (0.53) | CDKN1AKDM4ETLR8ALDH1A1BRAF | |
| SCHEMBL2108371 | 0.88 | CDKN1A (0.48) | CDKN1AKDM4ETLR8ALDH1A1BRAF | |
| Indiplon SCHEMBL30292630 | 0.85 | CDKN1A (0.61) | CDKN1AKDM4ETLR8ALDH1A1BRAF | |
| Indiplon SCHEMBL75094 | 0.85 | CDKN1A (0.61) | CDKN1AKDM4ETLR8ALDH1A1BRAF | |
| Indiplon SCHEMBL3714581 | 0.85 | CDKN1A (0.61) | CDKN1AKDM4ETLR8ALDH1A1BRAF | |
| Indiplon SCHEMBL4807177 | 0.84 | CDKN1A (0.60) | CDKN1AKDM4ETLR8ALDH1A1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081935-B1 | POLYMORPH B OF N-{2-FLUORO-5-[3-(THIOPHENE-2-CARBONYL)-PYRAZOLO[1,5-A]PYRIMIDIN-7-YL]-PHENYL}-N-METHYL-ACETAMIDE | FERRER INT (ES) | 2017-05-24 | — | — | EP | claimed |
| US-8530482-B2 | Halogenated pyrazolo[1,5-A]pyrimidines, processes, uses, compositions and intermediates | FERRER INTERNACIONAL, S.A. (ES) | 2013-09-10 | — | — | US | claimed |
| EP-2086978-B1 | AMORPHOUS FORM OF N-{2-FLUORO-5-[3-(THIOPHENE-2-CARBONYL)-PYRAZOLO [1,5-A]PYRIMIDIN-7-YL]-PHENYL-N-METHYL-ACETAMIDE | FERRER INT (ES) | 2013-01-23 | — | — | EP | claimed |
| US-8338436-B2 | Amorphous form of N-{2-fluoro-5-[3-(thiophene-2-carbonyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-phenyl}-N-methyl-acetamide | FERRER INTERNATIONAL, S.A. (ES) | 2012-12-25 | — | — | US | claimed |
| US-8273753-B2 | Polymorph B of N-{2-Fluoro-5-[3-(thiophene-2-carbonyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-phenyl}-N-methyl-acetamide | FERRER INTERNATIONAL, S.A. (ES) | 2012-09-25 | — | — | US | claimed |
| US-8039476-B2 | Polymorph B of N-{2-Fluoro-5-[3-(thiophene-2-carbonyl)-pyrazolo[1,5-a] pyrimidin-7-yl]-phenyl}-N-methyl-acetamide | FERRER INTERNACIONAL, S.A. (ES) | 2011-10-18 | — | — | US | claimed |
| US-20110224234-A1 | Polymorph B of N--N-methyl-acetamide | ANGLADA LUIS | 2011-09-15 | — | — | US | claimed |
| US-8008486-B2 | Process for the manufacture of a crystalline pyrazolo[1,5-a]pyrimidine compound | FERRER INTERNACIONAL, S.A. (ES) | 2011-08-30 | — | — | US | claimed |
| CN-101243089-B | Halopyrazolo [1,5-A ] pyrimidines, methods, uses as GABA-A receptor ligands, compositions and intermediate compounds | FERRER INT | 2011-07-06 | — | — | CN | claimed |
| EP-2081934-B1 | PROCESS FOR THE MANUFACTURE OF A CRYSTALLINE PYRAZOLO[1,5-A]PYRIMIDINE COMPOUND | FERRER INT (ES) | 2011-03-30 | — | — | EP | claimed |
| EP-1956021-A1 | Process for the manufacture of a crystalline pyrazolo[1,5-a]pyrimidine compound | FERRER INTERNACIONAL, S.A. (ES) | 2008-08-13 | — | — | EP | claimed |
| EP-1673084-B1 | 1-2' (1,4'-BIPERIDIN-1'-YL)-1-(PHENYL)-ETHYLCYCLOHEXANOL DERIVATIVES AS MONOAMINE REUPTAKE MODULATORS FOR THE TREATMENT OF VASOMOTOR SYMPTOMS | WYETH CORP (US) | 2008-07-09 | — | — | EP | claimed |
| WO-2008055934-A1 | AMORPHOUS FORM OF N-{2-FLUORO-5-[3-(THIOPHENE-2-CARBONYL)-PYRAZOLO [1,5-A]PYRIMIDIN-7-YL]-PHENYL-N-METHYL-ACETAMIDE | FERRER INTERNACIONAL, S.A. (ES) | 2008-05-15 | — | — | WO | claimed |
| EP-1921079-A1 | Amorphous form of N-{2-Fluoro-5-[3-(thiophene-2-carbonyl)-pyrazolo[1,5-a] pyrimidin-7-yl]-phenyl}-N-methyl-acetamide | FERRER INTERNACIONAL, S.A. (ES) | 2008-05-14 | — | — | EP | claimed |
| EP-1918290-A1 | Polymorph B of N-{2-Fluoro-5-[3-(thiophene-2-carbonyl)-pyrazolo[1,5-a] pyrimidin-7-yl]-phenyl}-N-methyl-acetamide | Ferrer Internacional, S.A. (ES) | 2008-05-07 | — | — | EP | claimed |
| WO-2008043799-A1 | PROCESS FOR THE MANUFACTURE OF A CRYSTALLINE PYRAZOLO[1,5-A]PYRIMIDINE COMPOUND | FERRER INTERNACIONAL, S.A. (ES) | 2008-04-17 | — | — | WO | claimed |
| WO-2008043800-A1 | POLYMORPH B OF N-{2-FLUORO-5-[3-(THIOPHENE-2-CARBONYL)-PYRAZOLO[1,5-A] PYRIMIDIN-7-YL]-PHENYL}-N-METHYL-ACETAMIDE | FERRER INTERNACIONAL, S.A. (ES) | 2008-04-17 | — | — | WO | claimed |
| EP-1899343-A1 | HALOGENATED PYRAZOLO [1,5-A]PYRIMIDINES, PROCESSES, USES AS GABA-A RECEPTORS LIGAND, COMPOSITIONS AND INTERMEDIATES | Ferrer Internacional, S.A. (ES) | 2008-03-19 | — | — | EP | claimed |
| WO-2006136530-A1 | HALOGENATED PYRAZOLO [1,5-A]PYRIMIDINES, PROCESSES, USES AS GABA-A RECEPTORS LIGAND, COMPOSITIONS AND INTERMEDIATES | FERRER INTERNACIONAL, S.A. (ES) | 2006-12-28 | — | — | WO | claimed |
| EP-1736475-A1 | Halogenated pyrazolo[1,5-a]pyrimidines, processes, uses, compositions and intermediates | FERRER INTERNACIONAL, S.A. (ES) | 2006-12-27 | — | — | EP | claimed |